

# Baseline quality of life predicts overall survival in patients with mCRPC treated with <sup>223</sup>Ra-dichloride

Viviana Frantellizzi<sup>1</sup> MD,  
 Maria Silvia De Feo<sup>2</sup> MD,  
 Arianna Di Rocco<sup>3</sup>,  
 Mariano Pontico<sup>4</sup> MD, PhD,  
 Arianna Pani<sup>5</sup> MD,  
 Alessio Farcomeni<sup>3</sup>,  
 Laura Cosma<sup>2</sup> MD,  
 Julia Lazri<sup>2</sup> MD,  
 Giuseppe De Vincentis<sup>2</sup> MD, PhD

1. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy  
 2. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy  
 3. Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy  
 4. Program in Morphogenesis & Tissue Engineering, "Sapienza" University of Rome, Rome, Italy  
 5. Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan "Statale", Italy

Keywords: Quality of Life  
 - Overall Survival - mCRPC - <sup>223</sup>Ra

## Corresponding author:

Viviana Frantellizzi MD,  
 Viale Regina Elena 324,  
 00161, Rome, Italy  
 viviana.frantellizzi@uniroma1.it  
 Tel: 0649978573, Fax: 0649978592

Received:

23 December 2019

Accepted revised:

10 March 2020

## Abstract

**Objective:** The prognostic value of baseline clinical parameters in predicting the survival prolonging effect of radium-223-dichloride (<sup>223</sup>Ra)-therapy in metastatic castration resistant prostate cancer (mCRPC) patients is still an open issue. The aim of this study was investigating the impact of baseline quality of life (QoL) on overall survival (OS) in mCRPC patients treated with <sup>223</sup>Ra. The present study also evaluated the trend of patient-reported QoL during both <sup>223</sup>Ra-treatment and post-therapy follow-up period. **Materials and Methods:** One hundred and seventy-three consecutive mCRPC patients treated with <sup>223</sup>Ra were included in this prospective study. Quality of life was assessed through EORTC QLQ-C30 and QLQ-BM22 questionnaires and 2264 questionnaires were evaluated. Other baseline variables relevant to the OS analysis have been considered. Data were summarized using descriptive statistics, univariate and multivariate analysis with Cox model. A principal component analysis (PCA) on the questionnaires' results compiled at baseline was performed to reduce the data to a one-dimensional score. Joint models for survival and longitudinal data were finally used in order to evaluate the relationship between the time-dependent QoL scores and OS. **Results:** On multivariate analysis, baseline patients' (hemoglobin) Hb, (total alkaline phosphatase) tALP, and two EORTC QLQ-C30 items, physical functioning (HR=0.970, CI=0.960-0.980, P<0.001) and dyspnea (HR=0.992, CI=0.986-0.999, P=0.023), were significantly associated with OS. In the resulting model of the multivariate analysis performed after PCA, baseline patients' Hb, tALP and QoL-score were independent significant predictors of OS (QoL-score: HR=0.995-95%CI=0.992 – 0.998, P=0.001). The OS analysis stratified by score of baseline QoL, showed a median OS of 8 (95%CI=6-11) and 16 (95%CI=12-24) months for scores respectively below and above the cut-off value (log-rank-P<0.001). The joint model showed a significant deterioration of QoL-score during both <sup>223</sup>Ra-therapy and follow-up period (P<0.001). **Conclusion:** Baseline QoL is a significant predictor of OS, meaning that patients with better pretreatment QoL are more likely to obtain a marked survival prolonging effect from <sup>223</sup>Ra.

Hell J Nucl Med 2020; 23(1): 14-19

Epub ahead of print: 7 March 2020

Published online: 5 April 2020

## Introduction

One metastases represent the end-stage of the disease for many patients with metastatic castration resistant prostate cancer (mCRPC) [1]. Such patients, dealing with disabling bone pain, hypercalcemia, spinal cord or nerve root compression, pathological fractures, and marrow failure, have poor prognosis and experience a significant worsening of their quality of life (QoL) [2, 3].

Radium-223-dichloride (<sup>223</sup>Ra), a bone-targeting alpha-particle emitter with low bone-marrow toxicity [4], showed its safety [5] and approved for treatment of mCRPC patients with symptomatic bone metastases and no evidence of visceral metastatic involvement [6], after the randomized phase III clinical trial (ALSYMPCA), showed palliative effect on bone pain and significant improvement of overall survival (OS) [7]. Survival gain represents the distinctive feature of <sup>223</sup>Ra-therapy, as compared to other palliative bone-targeting therapies, such as local radiation, strontium-89 (<sup>89</sup>Sr) and samarium-153 (<sup>153</sup>Sm)-EDTMP, zoledronic acid and denosumab, which have no impact on survival [8]. Although the role of <sup>223</sup>Ra in improving OS is well established, with a reported median survival extension of 3.6 months as compared with placebo, few reliable and validated prognostic factors have been currently identified [9]. Several baseline variables commonly used in clinical practice [10], such as Eastern Cooperative Oncology Group Performance Status (ECOG-PS), total alkaline phosphatase (tALP), hemoglobin (Hb) and number of prior systemic treatments, have been proposed [11]. To date, tALP is considered to be the most reliable marker of response during <sup>223</sup>Ra-treatment, but the prognostic value of pretreatment levels is still under investigation [12, 13]. A recent study proposed a three variable prognostic score as a valid multidimensional approach for predicting the

survival prolonging effect of  $^{223}\text{Ra}$ , by taking into account baseline patients' Hb, ECOG-PS and prostate specific antigen (PSA) [14]. In such scenario, identifying further reliable prognostic factors, became of primary importance. Patient reported QoL, intended as "patients" appraisal of and satisfaction with their current level of functioning compared to what they perceive to be possible or ideal [15], has become an important clinical parameter in management of cancer patients and is known to be a significant prognostic factor for patients with different cancers, such as lung cancer [16], colorectal cancer [17], cholangio and hepatocellular carcinoma [18], and head and neck cancer [19]. Nevertheless, little is known about the prognostic value of pretreatment baseline-QoL in patients with mCRPC prostate cancer undergoing palliative therapies, and no study has investigated the potential value of QoL-assessment in identifying subjects who are more suitable to receive the maximum survival benefit from  $^{223}\text{Ra}$ -therapy. The primary endpoint of this study was to evaluate the impact of pretreatment baseline QoL on OS, in mCRPC patients with symptomatic bone metastases receiving  $^{223}\text{Ra}$ -therapy. The present study also evaluated the trend of patient-reported QoL during both  $^{223}\text{Ra}$ -treatment and post-therapy follow-up.

## Materials and Methods

This study was approved by the local Ethical Committee and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. All patients signed a written Informed Consent. The present single-center prospective study enrolled 173 consecutive patients affected by symptomatic bone metastases from mCRPC, eligible for  $^{223}\text{Ra}$ -therapy [7, 20] and treated in our Nuclear Medicine Unit, from September 2013 to the time of the analysis (July 2018). Currently,  $^{223}\text{Ra}$ -therapy consists of an intravenous injection of 55KBq/Kg of body weight, dispensed every 28 days, for a total of 6 cycles [6]. Quality of life was evaluated by asking patients to answer both the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30, version 3.0), and the EORTC Bone Metastasis Module (QLQ-BM22). The inclusion criteria for this study were: all patients had an histological confirmation of prostatic adenocarcinoma, at least two symptomatic bone secondary lesions detected by technetium-99m-hydroxydiphosphonate ( $^{99\text{m}}\text{Tc}$ -HDP) bone scintigraphy and no known visceral metastases at contrast-enhanced CT scan, except for malignant lymphadenopathy with less than 3cm in the short-axis diameter, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2 and adequate hematological, hepatic and renal function. The unavailability of the baseline QoL assessment represented an exclusion criterion from the study. The QLQ-C30 questionnaire represents a specific tool for the assessment of QoL in cancer patients [21]. The QLQ-C30 (version 3.0) is composed of both multi-item scales and single item measures. These include 5 functional scales (cognitive,

CF; emotional, EF; physical, PF; role, RF; and social functioning, SF), 3 symptom scales (fatigue, FA; nausea/vomiting, NV; and pain, PA), a global health status/QoL scale and 5 single items assessing additional symptoms (appetite loss, AP; constipation, CO; diarrhea, DI; dyspnea, DY; and sleep disturbance, SL) and perceived financial impact, FI. Each of the multi-item scales includes a different set of items-no item occurs in more than 1 scale. All scales and single item measures range in score from 0-100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. The Bone Metastasis Module (QLQ-BM22) consists of an additional disease-specific module for patients with bone metastases [22]. The specific 22-item EORTC QLQ-BM22 questionnaire assesses disease symptoms related to bone metastasis, including painful sites, functional interference, painful characteristics, and psychosocial aspects as multi-item scales. We scaled all items from one (not at all) to four (very much). In this questionnaire, a higher score in the case of symptom scales is indicative of greater distress, while a higher score in the case of functional scales indicates greater functional ability. Questionnaires were completed by patients without any kind of conditioning from relatives or medical staff, and were submitted at baseline, at the end of each treatment cycle, and at each follow-up evaluation, performed at 3 months, 6 months and 12 months after the end of  $^{223}\text{Ra}$ -therapy. Among 173 patients enrolled, 5 were excluded from the study because of the unavailability of the baseline QoL assessment. Other baseline clinical data relevant to the OS analysis, specifically age, height, weight, Hb, platelets (PLT), ECOG-PS, PSA and tALP, have been collected and taken into account in the statistical analysis. Overall survival was established from the date of the first administration of  $^{223}\text{Ra}$  until the date of death from any cause. An OS analysis was also performed by dividing the population into patients who received up to 4 cycles and  $\geq 5$  cycles of  $^{223}\text{Ra}$ .

## Statistical analysis

Continuous variables were expressed as mean  $\pm$  standard deviation; categorical variables as absolute and percentage values. Overall Survival was defined as the time span from first administration of  $^{223}\text{Ra}$  until death from any cause or censoring at last follow-up time. The Kaplan-Meier estimator was used to estimate survival curves. Univariate analysis using a Cox regression model was used to assess potential prognostic factors. A multivariable Cox regression model was then estimated where the final set of predictors was selected based on minimization of the Akaike information criterion in stepwise selection stages. The stepwise selection criterion protects from collinearity issues, which were also checked for the final selected model using variance inflation factors. No issues with collinearity were present in the models reported. We performed a principal component analysis (PCA) on the questionnaires' results compiled at baseline to reduce the data to a one-dimensional score. Data reduction was done considering

the correlation matrix of the whole questionnaire with nineteen items (15 for the EORTC QLQ-C30 and 4 for the EORTC QLQ-BM22). Principal component analysis optimally assigns weights to each item, with each principal component (PC) resulting as a weighted linear combination of the original variables. The first PC has the largest possible variance and can be used as a univariate score summarizing the whole questionnaire. Data reduction was satisfactory as about 90% of total variance was captured by the first PC. Univariate and multivariate analyses using Cox models were then repeated to evaluate the role of the first principal component as a potential prognostic factor. Only baseline measurements were used for performing PCA in order to avoid attrition bias in estimating weights. Weights for the first PC were then used to build scores also at different follow-up times. In order to evaluate the relationship between the resulting time-dependent QoL scores and OS (and the relationship between trends and OS) we used Joint Models for survival and longitudinal data, where a single shared parameter captured the association of interest. Joint models allow to assess relationships with longitudinal markers and survival in an unbiased manner. The prognostic significance of the new scores was evaluated via time-dependent receiver operating characteristic (ROC) curves. The final cut-off was selected by maximizing the sum of sensitivity and specificity. A  $P < 0.05$  was considered as statistically significant and all tests were two-sided. All statistical analyses were performed with the software R version 3.5.1.

## Results

Baseline patients' characteristics are shown in Table 1. Among 168 patients, 108 patients (64%) had completed the 6 scheduled administrations, 48 patients (29%) had discontinued  $^{223}\text{Ra}$  because of progressive disease or death, while 12 (7%) were still receiving therapy at the time of the analysis. A total of 2264 questionnaires have been collected and analyzed, 1132 of which were EORTC QLQ-C30 and 1132 were QLQ-BM22. The median follow-up time from the first  $^{223}\text{Ra}$  treatment to either death or last contact (last  $^{223}\text{Ra}$  administration, last follow-up phone call or last follow-up technetium-99m-diphosphonate bone scan), was  $11 \pm 8$  months (range 1-38). Median OS time was 12 months (95%CI 10-13 months), as shown in Figure 1. The univariate analysis evaluating the prognostic value of all baseline clinical variables showed that patients' Hb, PLT, tALP, and PSA values were independently associated with an increased risk of death. As shown in Table 2, almost all items of both baseline EORTC QLQ-C30 and QLQ-BM22 questionnaires were significantly associated with OS on univariate analysis. Only age ( $P=0.095$ ), dyspnea ( $P=0.511$ ), diarrhea ( $P=0.055$ ) and financial difficulties ( $P=0.218$ ) were not significantly associated with improvement in OS. When adjusting for other measures on multivariate analysis, baseline patients' Hb, tALP, and two EORTC QLQ-C30 items (PF2-physical functioning and DY-dyspnea) were significantly associated with OS. After data re-

duction, the first PC explained 90% of the total variation, being then a satisfactory summary of the nineteen questionnaire items. The weights of the first PC are presented in Table 3. Each subject QoL score was calculated as the sum of the product of each loading and the corresponding item measurement. The score ranges from -222 to 200. The new QoL score showed good area under the curve (AUC 0.73); ROC curve is shown in Figure 2. The threshold selected by maximizing the sensitivity and specificity was 7. The entire cohort was stratified into two subgroups on the basis of the baseline QoL cut-off so obtained; the estimated overall survival and log-rank test show that patients with a baseline QoL  $< 7$  had a median OS time of 8 months (95%CI 6-11 months), while those with a baseline QoL  $\geq 7$  had a median OS time of 16 months (95%CI 12-24 months), showing a significant association between higher levels of baseline QoL and longer survival (log-rank  $P < 0.001$ ) (Figure 3). The baseline value of our QoL score was significantly associated with OS at univariate analysis (HR=0.993, 95% CI 0.991-0.996) with a  $P$  value  $< 0.001$  and when adjusting for other measures on multivariate analysis, baseline patients' Hb (HR=0.816, 95% CI 0.717-0.927), tALP (HR=1.008, 95% CI 1.003-1.013) and our QoL score (HR=0.995, 95% CI 0.992 - 0.998) were significantly associated with OS (Table 4). The joint model showed a significant deterioration of global-QoL during both  $^{223}\text{Ra}$ -therapy, and the follow-up period ( $P < 0.001$ ), as shown in Figure 4. Forty three patients received  $< 5$  cycles and 125 received  $\geq 5$  cycles of  $^{223}\text{Ra}$ . Our data showed an estimated median survival of 4 and 14 months for these patient groups respectively (Figure 5). The data obtained from the analysis of the subgroups, in terms of OS, showed a clear advantage for patients who received  $\geq 5$  cycles compared to those who received fewer cycles.

**Table 1.** Baseline patients' characteristics.

Baseline characteristics	Patients (n = 168)	%
<b>Age (years)</b>		
- Mean (sd)	73.38 $\pm$ 8.06	
<b>Hb (g/dl)</b>		
- Mean (sd)	11.97 $\pm$ 1.73	
<b>Plt (<math>\times 10^9/l</math>)</b>		
- Mean (sd)	243 $\pm$ 103.1	
<b>tALP (U/l)</b>		
- Mean (sd)	314.45 $\pm$ 346.61	
<b>PSA (ng/ml)</b>		
- Mean (sd)	228.83 $\pm$ 429.03	
<b>Time from diagnosis (years)</b>		
- Median	7	
<b>Time from pain onset (years)</b>		
- Median	2.8	

(continued)

<b>Gleason Score</b>			<b>Brief Pain Inventory</b>				
-	Mean (range)	8 (6-9)	<b>Pain Score</b>				
-	6	1	-	Low (0-3)	18	28	
-	7	15	-	Intermediate (4-7)	30	48	
-	8	19	-	Severe (8-10)	15	24	
-	9	13	<b>Prior docetaxel treatment</b>				
-	Unknown	15	24	-	Yes	33	53
<b>ECOG Performance Status</b>			-	No	30	47	
-	Mean (range)	1.3 (0-3)	<b>N of previous systemic treatments</b>				
-	0	6	9	-	0	14	22
-	1	37	59	-	1	21	33
-	≥2	20	32	-	2	16	25
<b>Skeletal burden</b>			-	≥3	12	20	
-	0-6 mets	5	8				
-	6-20 mets	50	80				
-	≥20 mets	8	12				


**Table 2.** Univariate and multivariable analysis of OS in relation to baseline variables

Covariates	Univariate Models HR (95% CI)	P value	Multivariable Models HR (95% CI)	P value
<b>Age (years)</b>	1.022 (0.996 – 1.048)	0.095		
<b>HB</b>	0.727 (0.648 – 0.816)	<0.001	0.809 (0.716 – 0.913)	0.001
<b>PLT</b>	1.002 (1.001 – 1.004)	0.019		
<b>tALP</b>	1.010 (1.006 – 1.015)	<0.001	1.007 (1.002 – 1.011)	0.005
<b>PSA</b>	1.007 (1.004 – 1.011)	<0.001		
<b>C30 Items</b>				
PF2, Physical functioning	0.970 (0.962 – 0.979)	<0.001	0.970 (0.960 – 0.980)	<0.001
RF2, Role functioning	0.983 (0.976 – 0.989)	<0.001		
EF, Emotional functioning	0.987 (0.979 – 0.997)	0.003		
CF, Cognitive functioning	0.988 (0.979 – 0.997)	0.009		
SF, Social functioning	0.987 (0.980 – 0.994)	<0.001		
QoL, Global Health Status	0.983 (0.973 – 0.992)	<0.001		
FA, Fatigue	1.015 (1.007 – 1.022)	<0.001		
NV, Nausea and Vomiting	1.013 (1.003 – 1.023)	0.010		
PA, Pain	1.017 (1.010 – 1.024)	<0.001		
DY, Dyspnea	1.002 (0.996 – 1.008)	0.511	0.992 (0.986 – 0.999)	0.023
SL, Insomnia	1.007 (1.001 – 1.013)	0.018		
AP, Appetite Loss	1.013 (1.006 – 1.019)	<0.001		
CO, Constipation	1.010 (1.004 – 1.016)	0.001		
DI, Diarrhea	1.009 (1.000 – 1.018)	0.055		
FI, Financial Difficulties	1.005 (0.998 – 1.012)	0.196		
<b>BM22 Items</b>				
- BMFI, Functional Interference	0.983 (0.975 – 0.991)	<0.001		
- BMPA, Psychosocial Aspects	0.984 (0.975 – 0.993)	0.001		
- BMPS, Painful Sites	1.015 (1.006 – 1.023)	0.001		
- BMPC, Pain Characteristics	1.015 (1.006 – 1.024)	0.001		

<b>Table 3.</b> Component loadings for the first variable.			
<b>Variable</b>	<b>Pc1</b>		
Pf2, Physical functioning	0.274	DY, Dyspnoea	-0.179
Rf2, Role functioning	0.278	SL, Insomnia	-0.215
EF, Emotional functioning	0.224	AP, Appetite Loss	-0.202
CF, Cognitive functioning	0.204	CO, Constipation	-0.165
SF, Social functioning	0.250	DI, Diarrhoea	-0.072
QoL, Global Health Status	0.228	FI, Financial Difficulties	-0.123
FA, Fatigue	-0.285	BMFI, Functional Interference	0.301
NV, Nausea and Vomiting	-0.182	BMPA, Psychosocial Aspects	0.242
PA, Pain	-0.277	BMPS, Painful Sites	-0.265
		BMPC, Pain Characteristics	-0.254

**Table 4.** Univariate and multivariable analysis of OS in relation to baseline variables and our QoL score

<b>Covariates</b>	<b>Univariate Models HR (95% CI)</b>	<b>P value</b>	<b>Multivariable Models HR (95% CI)</b>	<b>P value</b>
<b>Age (years)</b>	1.022 (0.996 – 1.048)	0.095		
<b>HB</b>	0.727 (0.648 – 0.816)	<0.001	0.816 (0.717 – 0.927)	0.002
<b>PLT</b>	1.002 (1.001 – 1.004)	0.019		
<b>tALP</b>	1.01 (1.006 – 1.015)	<0.001	1.008 (1.003 – 1.013)	0.001
<b>PSA</b>	1.007 (1.004 – 1.011)	<0.001		
<b>Our QoL Score</b>	<b>0.993 (0.991 – 0.996)</b>	<b>&lt;0.001</b>	<b>0.995 (0.992 – 0.998)</b>	<b>0.001</b>



**Figure 1.** Kaplan-Meier estimate showing overall survival in our cohort, with a 95% confidence interval in dashed lines.




Figure 2. ROC curve for baseline QoL score.




Figure 3. Kaplan-Meier estimate showing overall survival stratified by QoL cut-off.





Figure 4. Deterioration of global-QoL score during both <sup>223</sup>Ra-therapy, and the follow-up period.



**Figure 5.** Kaplan-Meier analysis underlines the clear advantage in the overall survival of the  $\geq 5$  cycles Group against the  $< 5$  Group.

## Discussion

The impact of the disease on patients' QoL, has become an important consideration in health care and a weighty factor in clinical management of cancer patients [23]. In recent years, the investigation whether baseline QoL-assessment, in addition to clinic-pathological factors, may improve prognostic stratification, has aroused a growing interest, and focused the attention on the development of reliable QoL-assessment questionnaires, designed to capture information directly from the respondent. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), is considered to be a valid self-completion questionnaire to reliably and accurately assess QoL in cancer patients and is to date one of the most widely adopted instruments in cancer research and clinical practice [24]. In several studies among patients with different cancer histologies, the EORTC QLQ-C30, often associated with disease-specific questionnaires, has proved to be a valid and reliable tool for the assessment of the correlation between QoL and OS. In a quality of life study among patients with gastroesophageal cancer, the appetite-loss item of the EORTC QLQ-C30, resulted to be a significant independent predictor of survival, highlighting the significant prognostic role of QoL measures in this patient population [25]. A study involving patients with platinum-resistant ovarian cancer (PROC) reported a median OS extension of 6.3 months and 6.0 months, in patients with better physical function score and lower abdominal/gastrointestinal symptom scores respectively [26]. The reported significant correlation of the abdominal/gastrointestinal domain of the ovarian specific questionnaire (OV28) [27] with OS, confirmed the importance of using a disease-specific instrument in the assessment of QoL, in order to better evaluate QoL aspects more strictly correlated with each particular type of cancer, exceeding the limits of a general questionnaire for all cancer patients. Similar findings are reported in a recent study among patients

with nasopharyngeal carcinoma treated with intensity modulated radiation therapy. In this study QoL was assessed by asking patients to answer the EORTC QLQ Head and Neck Cancer-Specific Module (H&N35) [28] in addition to the EORTC QLQ-C30 (version 3.0). A high pretreatment cognitive functioning score in QLQ-C30 was associated with longer local recurrence-free survival, while H&N35 pretreatment teething-ill and felt-ill were significantly correlated with progression-free survival and distant-free survival respectively [29]. For patients with bone metastases, particularly occurring in advanced breast, prostate, lung and renal cell cancers [30], pain represents a heavy burden, often responsible for a significant worsening of QoL. The pain-centered questionnaire EORTC bone metastases module (EORTC QLQ-BM22) was specifically designed as a supplement to the EORTC QLQ-C30 to evaluate the specific aspects of QoL impairment associated with bone metastases [31, 32]. The present study is the first analysis of the prognostic value of baseline QoL measures in mCRPC patients with symptomatic bone metastases treated with  $^{223}\text{Ra}$  and was performed by submitting to patients both the EORTC QLQ-C30 and the EORTC QLQ-BM22. In accordance with the above studies among patients with different advanced cancers, baseline QoL showed a significant correlation with OS in our patient population. The resulting model of the multivariate analysis performed after PCA, showed that among patients with the same clinical condition in terms of baseline Hb and tALP values, those with better self-reported QoL, are more suitable to obtain a greater survival benefit from  $^{223}\text{Ra}$ . In particular, as shown in the OS analysis stratified by score of baseline QoL, the median OS is significantly longer in patients with higher baseline QoL scores as compared to patients with lower scores, specifically 16 and 8 months of median OS respectively. A recent paper proposed a three-variable predictive score as a reliable and helpful tool for stratifying the expected OS of mCRPC patients treated with  $^{223}\text{Ra}$ , by taking into account the baseline arrangement of ECOG-PS, PSA and Hb [14]. In this study, however, we demonstrate that at multivariate

analysis the baseline PSA values are less significant than other variables such as Hb and tALP to predict OS. Our analysis, underlining the significant correlation between baseline QoL and OS, suggest that including the baseline QoL assessment in a multi-variable model of baseline clinicopathological factors, may add prognostic potential, thus improving mCRPC patients' stratification about prognosis. Considering that the effect of  $^{223}\text{Ra}$  on OS is known to be obtained only after at least five cycles, stratifying patients' expected OS is of fundamental importance [33]. The EORTC QLQ-C30, represents a valid and complete instrument, provides significant results, as reported in previous systematic reviews and allows QoL assessment at a minimal cost [34, 35]. In a previous paper, the QLQ-BM22 demonstrated to be a sensitive instrument for assessing palliative-radiotherapy benefits in patients with symptomatic bone metastases, by evaluating responders' QoL, before treatment and two months after treatment [36]. The pain domain of the QLQ-C30 and three out four domains of the QLQ-BM22, specifically painful sites, pain characteristics and functional interference, showed a significant improvement after treatment. This study confirmed the importance of using QLQ-BM22 as a bone metastases-specific tool when assessing QoL and evaluating response to palliative treatments in patients with symptomatic bone metastases. Our evaluation of QoL trend during  $^{223}\text{Ra}$ -therapy and follow-up period, performed through both the QLQ-C30 and the QLQ-BM22 questionnaire showed a global deterioration of QoL. These findings might be partially attributed to the inclusion of both responders and non-responders to  $^{223}\text{Ra}$  in terms of bone-pain relief, in the statistical analysis. However, as seen in another study, it is much more likely that the response to pain does not correlate with QoL [37]. Moreover, as we included all patients who had received at least one cycle of  $^{223}\text{Ra}$ , patients still in treatment were also evaluated, as well as patients with "flare phenomenon" in pain [38, 39], meaning that potential responders to treatment were included in the study before they obtained a significant benefit from all the 6 scheduled cycles of therapy. A patient-reported QoL analysis from the ALSY-MPCA study, performed with the general EuroQoL 5D (EQ-5D) questionnaire [40] and the disease-specific Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [41, 42], demonstrated that in patients undergoing  $^{223}\text{Ra}$ -therapy, improved survival is associated with a slower decline in QoL over time as compared to placebo [43]. Despite our study showed similar results and confirmed QoL deterioration over time in mCRPC patients treated with  $^{223}\text{Ra}$  from baseline during both therapy and follow-up period, different instruments have been employed for QoL evaluation. These considerations might put the attention on the development of a standardized method to be applied in QoL assessment, in order to optimize the sharing of comparable data on patients' QoL outcomes between different centers, thus improving both research and clinical practice. A possible limitation of the present study is the analysis conducted only in a single center among a limited sample of patients.

In conclusion, the survival gain in patients with bone metastases from CRPC treated with  $^{223}\text{Ra}$  is well established, but the identification of baseline variables that may predict the

individual response to treatment is a continuous challenge. In our analysis, the baseline QoL assessed through the EORTC QLQ-C30 and the EORTC QLQ-BM22, showed a significant correlation with OS, meaning that patients with better baseline QoL are more likely to obtain a marked survival prolonging effect from  $^{223}\text{Ra}$ -therapy. These findings suggest that patient-reported QoL measures, in addition to clinicopathological factors, may improve prognostic stratification in mCRPC patients undergoing  $^{223}\text{Ra}$ -therapy, thus influencing clinical decision-making process and patient-doctor communication about prognosis.

## Bibliography

- Sciarra A, Gentilucci A, Silvestri I et al. Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castration resistant prostate cancer: A critical review. *Medicine (Baltimore)* 2019;98(19): e15608.
- Costa L, Badia X, Chow E et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. *Support Care Cancer* 2008; 16(8): 879-89.
- Sciarra A, Gentilucci A, Salciccia S et al. Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis. *Urol Oncol* 2018; 36(7): 340.e347-340.e321.
- Kerr C.  $^{223}\text{Ra}$  targets skeletal metastases and spares normal tissue. *The Lancet Oncology* 2002; 3(8): 453.
- De Vincentis G, Follacchio GA, Frantellizzi V et al.  $^{223}\text{Ra}$ -dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. *Aging Clin Exp Res* 2017; 30(6): 677-80.
- Du Y, Carrio I, De Vincentis G et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging* 2017; 44(10): 1671-8.
- Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369(3): 213-23.
- Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. *The Lancet Oncology* 2005; 6(6): 392-400.
- Wong WW, Anderson EM, Mohammadi H et al. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. *Clin Genitourin Cancer* 2017; 15(6): e969-e975.
- Prelaj A, Rebuzzi SE, Buzzacchino F et al. Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. *Oncol Lett* 2019; 17(2): 1467-76.
- Etchebehere EC, Araujo JC, Fox PS et al. Prognostic Factors in Patients Treated with  $^{223}\text{Ra}$ : The Role of Skeletal Tumor Burden on Baseline  $^{18}\text{F}$ -Fluoride PET/CT in Predicting Overall Survival. *J Nucl Med* 2015; 56(8): 1177-84.
- Fizazi K, Massard C, Smith M et al. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. *Eur Urol* 2015; 68(1): 42-50.
- Hague C, Logue JP. Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases. *Ther Adv Urol* 2016; 8(3): 175-80.
- Frantellizzi V, Farcomeni A, Follacchio GA et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with  $^{223}\text{Ra}$ -dichloride. *Ann Nucl Med* 2018; 32(2): 142-8.
- Cella DF, Cherin EA. Quality of life during and after cancer treatment. *Compr Ther* 1988; 14(5): 69-75.
- Fiteni F, Vernerey D, Bonnetain F et al. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. *Eur J Cancer* 2016; 52: 120-8.
- Fournier E, Jooste V, Woronoff AS et al. Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study. *Dig Liver Dis* 2016; 48(1): 87-93.
- Steel JL, Geller DA, Robinson TL et al. Health-related quality of life as a prognostic factor in patients with advanced cancer. *Cancer* 2014; 120(23): 3717-21.

19. Karvonen-Gutierrez CA, Ronis DL, Fowler KE et al. Quality of life scores predict survival among patients with head and neck cancer. *J Clin Oncol* 2008; 26(16): 2754-60.
20. Baldari S, Boni G, Bortolus R et al. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. *Crit Rev Oncol Hematol* 2017; 113: 43-51.
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; 85(5): 365-76.
22. Zeng L, Chow E, Bedard G et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. *Int J Radiat Oncol Biol Phys* 2012; 84(3): e337-342.
23. De Vincentis G, Monari F, Baldari S et al. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. *Fut Oncol* 2018; 14(27): 2821-32.
24. Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. *Eur J Cancer* 2002; 38 Suppl 45125-33.
25. Mckernan M, Mcmillan DC, Anderson JR et al. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastroesophageal cancer. *Br J Cancer* 2008; 98(5): 888-93.
26. Roncolato FT, Gibbs E, Lee CK et al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA sub-study. *Ann Oncol* 2017; 28(8): 1849-55.
27. Greimel E, Bottomley A, Cull A et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. *Eur J Cancer* 2003; 39(10): 1402-8.
28. Bjordal K, De Graeff A, Fayers PM et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. *Eur J Cancer* 2000; 36(14): 1796-807.
29. Guo SS, Hu W, Chen QY et al. Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. *BMC Cancer* 2018; 18(1): 114.
30. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006; 12(20 Pt 2): 6243s-6249s.
31. Chow E, Bottomley A. Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. *Expert Rev Pharmacoecon Outcomes Res* 2009; 9(5): 461-5.
32. Roviello G, Gallicchio R, Bozza G et al. Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. *Onco Targets Ther* 2018; 12: 9-13.
33. Sartor O, Vogelzang NJ, Sweeney C et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. *Oncologist* 2018; 23(2): 193-202.
34. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol* 2008; 26(8): 1355-63.
35. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. *Health Qual Life Outcomes* 2009; 7: 102.
36. Mendez LC, Raman S, Wan BA et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort. *Ann Palliat Med* 2017; 6(Suppl 1): S65-S70.
37. De Vincentis G, Frantellizzi V, Follacchio GA et al. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with <sup>223</sup>Radium. *Eur J Cancer Care (Engl)* 2019; 28(5): e13112.
38. Mcnamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. *BMC Cancer* 2015; 15: 371.
39. De Vincentis G, Follacchio GA, Frantellizzi V et al. Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report. *Clinical Genitourinary Cancer* 2016; 14(5): e529-e533.
40. EuroQol—a new facility for the measurement of health-related quality of life. *Health policy (Amsterdam, Netherlands)* 1990; 16(3): 199-208.
41. Cella D, Nichol MB, Eton D et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. *Value Health* 2009; 12(1): 124-9.
42. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993; 11(3): 570-9.
43. Nilsson S, Cislo P, Sartor O et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. *Ann Oncol* 2016; 27(5): 868-74.